Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The employee options carry an exercise price equal to the grant-date closing price and require continued service to vest.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (ZNTL) granted stock options to purchase 62,000 common shares to three newly hired employees on October 1, 2026.
The awards were made under the 2022 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The exercise price is $2.605 per share, equal to the stock’s closing price on the grant date. The options have a 10-year term and vest over four years: 25% on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the next three years. Vesting requires continued service on each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options for 62,000 common shares at $2.605 per share create potential dilution if exercised.
Key Figures
- Options granted
- 62,000 shares
- Granted to three newly hired employees
- Exercise price
- $2.605 per share
- Equal to the closing price on the grant date
- Option term
- 10 years
- Stock options
- Vesting schedule
- 25% on the first anniversary; remaining 75% in equal monthly installments over the next three years
- Subject to continued employee service
Historical Context
-
Earlier grants under the same plan used a 10-year term and four-year vesting schedule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-qualified stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock options did Zentalis grant to new employees on October 1, 2026?
Zentalis granted three newly hired employees options to purchase an aggregate of 62,000 common shares at an exercise price of $2.605 per share. The options have a 10-year term and were awarded under the 2022 Employment Inducement Incentive Award Plan.
How do Zentalis’s October 1, 2026 employee stock options vest?
The options vest over four years, subject to continued service on each vesting date. A total of 25% vests on the first anniversary of the vesting commencement date, and the remaining 75% vests in equal monthly installments over the three years thereafter.
Who is eligible for Zentalis’s 2022 Employment Inducement Incentive Award Plan?
The plan is exclusively for individuals who were not previously Zentalis employees or who join following a bona fide period of non-employment. Awards must be a material inducement to entering employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).